BioCryst to Present New HAE Real-World Evidence at ISPOR 2026
BioCryst Pharmaceuticals announced it will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference. The studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs. Findings indicate children with HAE experience greater healthcare resource utilization, including outpatient visit rates more than three times higher than controls, and caregivers spend over 20 hours weekly providing care, with greater impacts on their quality of life during frequent HAE attacks. This research reinforces the importance of optimized disease management.
Key Highlights
- BioCryst to present two new real-world evidence posters on hereditary angioedema (HAE) at the ISPOR 2026 conference from May 17 extendash20.
- Studies highlight the significant healthcare and quality-of-life burden of HAE in pediatric patients and their caregivers.
- First study analyzed Komodo claims data from 2016 to 2024, including over 400 children aged 2 to <12 years with HAE.
- Children with HAE experienced greater healthcare resource utilization (HCRU), with outpatient visit rates more than three times higher.
- Second study found caregivers spend an average of over 20 hours per week providing care for children with HAE.
- Caregivers reported greater impacts on health-related quality of life during periods of more frequent HAE attacks.
Price Impact
More from BCRX